Calcimimetics in chronic kidney disease: evidence, opportunities and challenges.

@article{Evenepoel2008CalcimimeticsIC,
  title={Calcimimetics in chronic kidney disease: evidence, opportunities and challenges.},
  author={P Evenepoel},
  journal={Kidney international},
  year={2008},
  volume={74 3},
  pages={265-75}
}
Secondary hyperparathyroidism (SHPT) remains a highly prevalent and important complication in patients with chronic kidney disease (CKD). Indeed, SHPT may compromise bone health and contribute to the increased cardiovascular risks of these patients. Calcimimetic agents may help to control SHPT and to achieve the stringent mineral metabolism targets in patients with CKD stage 5D. Whether this will translate in improved patient-level outcomes remains to be demonstrated in adequately powered… CONTINUE READING